The selected pathophysiological aspects of PPARs activation

Journal of Physiology and Pharmacology

Volumn 56, Issue 2, 2005, Pages 149-162

  Kiec Wilk B ^a   Dembinska Kiec A ^a   Olszanecka, A ^a   Bodzioch, M ^a   Kawecka Jaszcz, K ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Diabetes mellitus; Heart hypertrophy; Hypertension; Lipotoxicity; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; FIBRIC ACID DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; TRANSCRIPTION FACTOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; DIABETES MELLITUS; GLUCOSE METABOLISM; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOTOXICITY; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN FAMILY; RECEPTOR UPREGULATION; REVIEW; TOXICITY;

ANIMALS; ARTERIOSCLEROSIS; CARDIOMEGALY; DIABETES MELLITUS; GLUCOSE; HUMANS; HYPERTENSION; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 21344434794     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Bishop-Bailey D, Hla T, Warner TD. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 2002;91:210-217.
2. Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 2002;4:163-174.
3. Heim M, Johnson J, Boess F, et al. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J 2002;16:718-20.
4. Sparks RL, Strauss EE, Zygmunt AI, Phelan TE. Antidiabetic AD4743 enhances adipocyte differentiation of 3T3 T mesenchymal stem cells. J Cell Physiol 1991;146:101-109.
5. El-Omar MM, Lord R, Draper NJ, Shah AM. Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy. Eur J Heart Fail 2003;5:229-39.
6. Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003;88:2412-21.
7. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003;100:1226-31.
8. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-1257.
9. Tarrade A, Schoonjans K, Pavan L, et al. PPARgamma/RXRalpha heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001;86:5017-5024.
10. Abe M, Hasegawa K, Wada H, et al. GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:404-410.
11. Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol 2002;16:707-721
12. Li L, Beauchamp MC, Renier G. Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 2002;165:101-110.
13. Youssef J, Badr M. Role of Peroxisome Proliferator-Activated Receptors in Inflammation control. J Biomed Biotechnol 2004;3:156-166.
14. Duval C, Fruchart JC, Staels B. PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss 2004;97:665-672.
15. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002;59:790-798.
16. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002;51:718-723.
17. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121.
18. Goetze S, Bungenstock A, Czupalla C, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002;40:748-754.
19. Sabatini M, Bardiot A, Lesur C, et al. Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage 2002;10:673-679.
20. Mossner R, Schulz U, Kruger U, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002;119:576-582.
21. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W, Toge T. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res 2003;23:267-73.
22. Placha W, Gil D, Dembinska-Kiec A, Laidler P. The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 2003;13:447-456.
23. Konturek PC, Brzozowski T, Kania J, et al. Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat. Scand J Gastroenterol 2003;38:468-476.
24. Ciaraldi TP, Cha BS, Park KS, Carter L, Mudaliar SR, Henry RR. Free fatty acid metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists Ann NY Acad Sci 2002;967:66-70.
25. Malczewska-Malec M, Kwaśniak M, Leszczynska-Golabek I, Kiec-Wilk B, Partyka L, Dembinska-Kiec A. Hypertension, postprandial lipemia and gene polymorphism in obese families. Moduzzi Editore 2002;529-534.
26. Foucher C, Rattier S, Flavell DM, et al. Influence on genetic polymorphisms on fenofibrate response. Second International Symposium on PPARs: From Basic Science to Cilinical Applications Florence, Italy; March 19-22; 2003 (abstract).
27. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002;105:1440-1445.
28. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep 2002;4:514-521.
29. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551-559.
30. Kudzma DJ. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus. Am J Manag Care 2002;8:S472-S482.
31. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-474.
32. Moore KJ, Fitzgerald ML, Freeman MW. Peroxisome proliferator-activated receptors in macrophage biology: friend or foe? Curr Opin Lipidol 2001;12:519-527
33. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, Kuroki T, Schonthal AH, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21 (Cip 1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. J Biol Chem 2001;276:47650- 47657.
34. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405: 421-424.
35. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-595.
36. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-1257.
37. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30.
38. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003;100:15924-15929.
39. Rana BS, Band MM, Ogston S, Morris AD, Pringle SD, Struthers AD. Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. Am J Cardiol 2002;90:483-487.
40. Davis CL, Kapuku G, Snieder H, Kumar M, Treiber FA. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci 2002;324:72-75
41. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002;90:11G-18G.
42. Tengholm A, Meyer T. A PI3-kinase signaling code for insulin-triggered insertion of glucose transporters into the plasma membrane. Curr Biol 2002;12:1871-1876.
43. Way KJ, Isshiki K, Suzuma K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002;51:2709-2718.
44. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 2002;7:175-185.
45. Kintscher U, Schupp M, Pregla R. et al. Increased cardiac PPARα expression in overweihght/obese humans. Second International Symposium on PPARs: From Basic Science to Clinical Applications Florence, Italy; March 19-22; 2003 (abstract).
46. Carvajal K, Moreno-Sanchez R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res 2003;34:89-99.
47. Dekkers JC, Treiber FA, Kapuku G, Snieder H. Differential influence of family history of hypertension and premature myocardial infarction on systolic blood pressure and left ventricular mass trajectories in youth. Pediatrics 2003;111: 1387-1393.
48. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003;91:9G-14G.
49. Nicol RL, Frey N, Olson EN. From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu Rev Genomics Hum Genet 2000;1:179-223.
50. Pellieux C, Foletti A, Peduto G, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001;108:1843-1851.
51. Peng H, Moffett J, Myers J, et al. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 2001;12:449-462.
52. Missault LH, De Buyzere ML, De Bacquer DD, Duprez DD, Clement DL. Relationship between left ventricular mass and blood pressure in treated hypertension. J Hum Hypertens 2002;16:61-66.
53. Verdecchia P, Clement D, Fagard R, Palatini P, Parati G. Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality. Blood Press Monit 1999;4:303-317.
54. Kagiyama S, Qian K, Kagiyama T, Phillips MI. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 2003;41:824-829.
55. Daniels SR, Witt SA, Glascock B, Khoury PR, Kimball TR. Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr 2002;141:186-190.
56. Cybulski G, Niewiadomski W. Influence of age on the immediate heart rate response to the active orthostatic test. J Physiol Pharmacol 2003;54:65-80.
57. Agabiti-Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001;10:288-298.
58. Otto ME, Belohlavek M, Khandheria B, Gilman G, Svatikova A, Somers V. Comparison of right and left ventricular function in obese and nonobese men. Am J Cardiol 2004;93:1569-1572.
59. Kinoshita N, Onishi S, Yamamoto S, et al. Unusual left ventricular dilatation without functional or biochemical impairment in normotensive extremely overweight Japanese professional sumo wrestlers. Am J Cardiol 2003;91:699-703.
60. Contaldo F, Pasanisi F, Finelli C, de Simone G. Obesity, heart failure and sudden death. Nutr Metab Cardiovasc Dis 2002;12:190-197.
61. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-1730.
62. Takano H, Hasegawa H, Nagai T, Komuro I. The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy. Drugs Today (Barc) 2003;39:347-357.
63. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 2002;103:284S-288S.
64. Anstadt MP, Hutchinson J, Portik-Dobos V. et al. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn Dis 2002;12:S3-S5.
65. Kurzelewski M, Duda M, Stanley WC, Boemke W, Beresewicz A. Nitric oxide synthase inhibition and elevated endothelin increase oxygen consumption but do not affect glucose and palmitate oxidation in the isolated rat heart. J Physiol Pharmacol 2004;55:27-38.
66. Jamshidi Y, Montgomery HE, Hense HW, et al. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2002;105:950-955.
67. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52-57.
68. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003;23:45-51.
69. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002;40:822-831.
70. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002;105:1240-1246.
71. Wexberg P, Pacher R, Rodler S, et al. Intimal hyperplasia and coronary flow reserve after heart transplantation: association with big endothelin-1. J Heart Lung Transplant 2002;21:1257-1263.
72. Robins SJ. Va-HIT and the case for fibrates as preferential therapy for diabetes and the metabolic syndrome. Second International Symposium on PPARs: From Basic Science to Clinical Applications Florence, Italy; March 19-22; 2003 (abstract).